MediciNova’s MN-001 for IPF Fails to Slow Lung Function Decline

MediciNova’s MN-001 for IPF Fails to Slow Lung Function Decline

Six months of treatment with MN-001 (tipelukast), MediciNova’s investigational oral therapy, failed to significantly improve lung function in adults with idiopathic pulmonary fibrosis (IPF), according to data from a small Phase 2 clinical trial. The therapy, however, was associated with some positive effects, such as a reduction in worsening IPF…

Daily Breathing Exercises Seen to Slow Progression in IPF Patients

Simple breathing exercises as an add-on therapy can safely slow lung function decline and improve quality of life in people with mild to moderate idiopathic pulmonary fibrosis (IPF), a small study reported. After six months of disease-tailored and daily breathing exercises, participants showed significant gains in several measures of…

Register Now for Global Genes’ RARE Patient Advocacy Summit

Registration is now open for Global Genes‘ 2021 RARE Patient Advocacy Summit. This year’s hybrid event will be livestreamed from California Sept. 27-29, and some seats also are available for attending the event in person in San Diego. “Here you’ll have the opportunity to connect and engage with others…

Serious Mortality, Ventilation Risk Seen in IPF Patients With COVID-19

People with idiopathic pulmonary fibrosis (IPF) infected with SARS-CoV-2, the virus that causes COVID-19, are at a greater risk of severe illness leading to mechanical ventilation or death than are infected patients without this progressive lung disease, a large database study reported. Among hospitalized individuals, however, its scientists saw…

Adapting and Moving Through Tough Days

In March 2019, my mom, Holly, got a second chance at life. Her bilateral lung transplant was a gift of the highest order. It saved and prolonged her life when nothing else would. It gave her body back the power to enjoy living. It restored her health and independence.

Blood Levels Marking Collagen Turnover May Predict IPF Severity

The degree of collagen degradation, a process called collagen turnover, evident in a person’s blood at the time idiopathic pulmonary fibrosis (IPF) is diagnosed predicts the severity of disease progression within one year, regardless of antifibrotic treatment, a study reported. These findings support the use of collagen turnover as a blood…

Pulmonary Fibrosis Alters the Trajectory of Our Lives

Many significant milestones in life occur during young adulthood. Some may buy their first home, get married, and start a family, which is a typical trajectory. Unfortunately, idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease, doesn’t care about typical trajectories. It unapologetically interferes with the lives of patients…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums